Immunoglobulin A deficiency (IgAD), the most prevalent primary immunodeficiency in Caucasian populations, shows strong evidence of polygenic inheritance with several associated genes being located in the major histocompatibility complex (MHC). Our aims were to determine which previously described MHC associations were primary and not secondary to a decrease or an increase in other MHC haplotype frequencies, to study the genetic interactions between all disease-associated MHC haplotypes and, finally, to ascertain the relative importance of protection vs susceptibility. A relative predispositional effect (RPE) study showed that in addition to the primary positive association of IgAD with HLA-DRB1 * 0102, DR3/TNFa2b3, and DR7 carrying haplotypes, DRB1 * 1501 was a marker of a primary protective factor in the Spanish population. Our data also indicate that the combined presence in an individual of two MHC susceptibility haplotypes notably increases the predisposition to the disease and that DRB1 * 1501 positive haplotypes eliminate the susceptibility conferred by any other MHC haplotype.
Immunoglobulin A deficiency (IgAD) is the most prevalent primary immunodeficiency in the Spanish and other Caucasian populations. 1 Genetic studies have unraveled a clear major histocompatibility complex (MHC) genetic component. 1 Although the genes responsible for the increased susceptibility to IgAD are not known, they have been seen associated with HLA-DR1-, -DR3-and -DR7-positive MHC haplotypes and some authors have suggested that HLA-DR2 was associated with protection. 2 A recent report from our group 3 indicated that there are distinct MHC susceptibility genes, located in different regions on different MHC haplotypes. On HLA-DR1-and -DR7-positive haplotypes, the susceptibility locus mapped to the class II region, whereas on haplotypes carrying HLA-DR3, it mapped to the telomeric end of the class III region in strong association with the TNFa2b3 microsatellite alleles.
The study of resistance genes in polygenic diseases lags well behind the analysis of susceptibility factors, but a few examples are known. For instance, the DRB1 * 1501/ DQB1 * 0602 haplotype confers protection against type I diabetes mellitus, 4 and the extended MHC haplotype HLA-B7/DRB1 * 1501 has been shown to carry on its class III region a gene that diminishes susceptibility to multiple sclerosis 5 and protects against achalasia. 6 Nevertheless, it has to be noted that when one or several haplotypes in a region appear associated with a disease, this can create misleading deviations in the frequencies of other haplotypes. To distinguish between these secondary deviations in the frequencies and a truly genuine (positive or negative) association, a stepwise procedure called relative predispositional effects (RPEs) has been developed. 7 This method proceeds in several rounds of case-control comparisons, haplotypes showing the strongest associations being sequentially removed from the analysis. However, when this approach is used in a classically designed case-control study, the problem of low number of samples in the last rounds arises.
Moreover, in case-control studies, association between a disease and a genetic marker can arise as an artifact of population structure, and genetic linkage cannot be shown. Therefore, we thought a family-based study was warranted. Some recent studies on IgAD genetics had already been performed in families, but they had focused either on a single family 8 or on a single haplotype. 9 There has been no study analyzing together all susceptibility and resistance markers reported within the MHC on a family basis.
We have studied 183 IgAD patients as defined by the World Health Organization Group on Primary Immunodeficiencies, 10 all ascertained at the Immunology Unit of La Paz Hospital (Madrid) and 342 healthy controls. All patients and controls were unrelated Spanish Caucasians and both groups were essentially the same studied in a previous report. 3 Additionally, we studied parents and siblings of 100 of these patients. All parental MHC haplotypes could be established in these families (n ¼ 400). Those present among IgAD children or affected parents (n ¼ 212) were defined as 'IgAD' haplotypes. The remaining parental haplotypes (n ¼ 188) were defined as 'control' haplotypes, the so-called AFBAC (affected family-based controls) method. 11 The study was approved by the hospital ethics committee. Contrarily, three HLA-DR groups (DR2, DR5, and DR8) were found to be at higher frequency in the control haplotypes. In order to ascertain whether any of the positive or negative associations were secondary to the deviations in the frequencies of other alleles, we performed a step-by-step analysis.
A hierarchy of associated haplotypes, marked by their HLA-DR alleles was obtained with an haplotypic RPEs. 7 With this method, the most associated haplotype (the haplotype with the highest w 2 value and Po0.05) was sequentially removed from both IgAD and control haplotypes, and then a new round of w 2 and P-values was recalculated. The process ends when no remaining haplotype is differently distributed in IgAD compared to control haplotypes.
This study (Table 1 first through third round) showed that positive associations with all three haplotypes were not artifactually caused by another hypothetical protective haplotype. When all three susceptibility haplotypes were removed, a significant decrease in frequency was still observed for HLA-DR2 (Table 1 , fourth round). This showed as well that this was a true protective association, not secondary to the presence of the positively associated haplotypes. As DR2 had already been reported to be a protective allele, no Bonferroni correction was performed. In contrast, the lower frequencies of DR5 and DR8 lost their significance, and they were considered secondary to the other associations and not dissected further in this study.
When the HLA-DR2-positive samples were specifically typed for the individual subgroup alleles (HLA-DRB1 * 1501, * 1502, * 1601, and * 1602 alleles), a statistically significant difference was only found for HLA-DRB1 * 1501, the most frequently observed DR2 subtype in our population (0/88 in IgAD vs 10/154 in controls,
It is known that gene interactions modulate the susceptibility to polygenic diseases. In Crohn's disease, different mutations in the NOD2 gene notably increase disease susceptibility when combined in an individual. 18, 19 In type I diabetes mellitus, the protective effect of the HLA-DQB1 * 0602 allele appears to be dominant over susceptibility conferred by HLA-DR3/DR4. 20 However, in IgAD no attempt has been made to investigate the interactions between susceptibility and protective genetic factors.
After having identified, in a family-based study, the most relevant positive and negative MHC susceptibility factors, we investigated in a case-control study their interactions in different genotypic contexts. We first studied the strength of the susceptibility caused by each individual factor. The strongest positive association was found between IgAD-and HLA-DRB1 * 0102-positive genotypes, whereas the other two did not fall within the DRB1 * 0102 odds ratio (OR) 95% confidence interval ( Table 2) . As DR3/TNFa2b3/B8 is a very well-conserved extended haplotype, all individuals carrying it are expected to have essentially identical DNA, at least over the HLA-DR/DQ-HLA-B genomic region, and are, therefore, expected to carry the same susceptibility gene/s. Hence, the different risk conferred by DRB1 * 0102-and DR3/TNFa2b3-positive genotypes is another datum pointing to different susceptibility genes being carried by each genotype (see Table 2 ). For HLA-DR7-positive heterozygous genotypes, relative risk is even lower (RR ¼ 3.2), but as there are several extended haplotypes carrying this allele, there is always the possibility that not all of them carry the susceptibility gene/s.
We then studied whether, in the population carrying a MHC susceptibility factor, the combined presence, in the same individual, of a second MHC susceptibility factor (either the same or a different susceptibility factor), increased the risk for IgAD. As can be seen in Table 2 , 48 out of 147 (32.7%) IgAD patients carrying genotypes with an MHC susceptibility factor carried a second MHC susceptibility factor as compared to 15 out of 137 (10.9%) controls (P ¼ 0.00001; OR ¼ 3.94).
We then calculated the relative risks conferred by each combination of the two susceptibility factors. When a combination was present in less than 10 controls, its genotypic frequency was estimated under the assumption of Hardy-Weinberg equilibrium with the formulas , DR3-TNFa2b3 and DR7, respectively. Therefore, the RR was greatly enhanced when two doses of the susceptibility factors were present either in homo-or heterozygosity. Although for each individual genotype, 95% confidence interval was very large and no statistically significant results could be obtained, the data were rather impressive and added to that of their sum shown in the previous paragraph (P ¼ 0.00001; OR ¼ 3.94) point to a dose-related effect in most instances. It has been recently reported, 17 studying individuals positive for the HLA-DR3/B8 haplotype, that increased frequencies of IgAD are only found in homozygotes for this conserved, extended haplotype and have suggested a recessive inheritance with a low penetrance. Although we have observed that all three susceptibility MHC haplotypes (those carrying either DRB1 * 0102, DR7, or DR3-TNFa2b3) are sufficient for conferring susceptibility to IgAD, we also see that they are greatly influenced by genes on the other MHC haplotype, and the strong dosage effect of the HLA-DR3/B8 haplotype has to be acknowledged.
The small ORs of DR3-TNFa2b3 and DR7 in heterozygosity, and the notably increased risk when two doses of these haplotype markers, irrespective of them being in homo-or heterozygosity, exist in the same individual would suggest that DR3-TNFa2b3 and DR7 might be functionally equivalent. However, as our previous data DNA was isolated by standard methods from peripheral blood leukocytes. DRB1, DQA1, and DQB1 typing was carried out by polymerase chain reaction (PCR) amplification and hybridization with allelespecific oligonucleotides. 12 The TNFa and b microsatellites typing was performed with primers described previously. 13 The PCR fragments were subsequently run on an ABI Prism 310 automatic sequencer. DR2 subtyping was performed by a Taq-Man assay. 14 show that IgAD susceptibility genes on DR3-TNFa2b3 and DR7-positive haplotypes are different, we can speculate that these two genes might perform related functions.
As we mentioned above, HLA-DR2, and its subtype DRB1 * 1501, were the only markers found in statistically significant negative association with IgAD in the RPE study. DRB1 * 1501 is a subtype of HLA-DR2, and thus a much more accurate genetic entity than DR2. Therefore, we decided to investigate the protective role of DRB1 * 1501, when present together with any of the three independent susceptibility markers, or in their absence (see Table 3 ). It was rather impressive to observe that in individuals with a susceptibility marker, DRB1 * 1501 was not present in any patient as compared to 10.9% in controls (P ¼ 0.002; OR (CI) ¼ 0 (0.00-0.36)). As also shown in Table 3 , in individuals without any susceptibility marker, DRB1 Therefore, our data indicated that this protection was dominant over susceptibility and acted upon the three susceptibility haplotypes. As different haplotypes carry distinct susceptibility genes, the protective gene marked by HLA-DRB1 obviously cannot be an allelic variant of all those genes, but must instead (at least in some instance) be a different gene. We would refer to the genetic interaction between HLA-DRB1 * 1501 and the susceptibility alleles located in the MHC as epistasis. When the alleles of two genes show some degree of epistasis, they probably act in the same or related biological pathways. The 'dominant' or epistatic gene (in this case HLA-DRB1 * 1501) is usually placed downstream in the pathway, closer to the final phenotypic outcome. 21 HLA-DRB1 * 1501/DQA1 * 0102/DQB1 * 0602, the main DR2 haplotype, has been described as a resistance factor in insulin-dependent diabetes mellitus (IDDM). Moreover, its most frequent conserved, extended haplotype in our population (HLA-B7/DRB1 * 1501) harbors a resistance allele for multiple sclerosis and achalasia. 5, 6 The protective element in IgAD seems to be more related to the one found in diabetes mellitus, as it seems not to be confined to the HLA-B7/DRB1 * 1501 haplotype, but instead to be present in every HLADRB1 * 1501-positive haplotype.
In summary, we have studied the positive and negative associations of IgAD with MHC genes and haplotypes. As in many other immunologically mediated diseases, we have found important associations with MHC. However, as any other genetically complex disease, other genes in other chromosomes are also likely to be involved in IgAD susceptibility. Concerning the MHC genes, our results show that several genes are primarily involved in IgAD and that there are important interactions between them. HLA-DRB1 * 1501, seen as the only protective association, has a dominant protective effect. In addition, there are several genes in different MHC haplotypes associated with different degrees of susceptibility. This susceptibility appears greatly enhanced when two of these haplotypes appear in compound genotypes either in homo-or heterozygosity, but is completely wiped out when DRB1 * 1501 is present. The important epistatic effects between all these MHC genes in IgAD suggest that they probably act in the same or related biological pathways. 
